LACTOLOGY FOUNDATION

Cimetropium bromide (ATC A03BB05) is a peripherally acting antimuscarinic belladonna derivative used as an antispasmodic for functional gastrointestinal disorders, with limited data but probable compatibility with breastfeeding when used short term and at standard doses.pubchem.ncbi.nlm.nih+7

Pharmacological profile

Cimetropium bromide is a semisynthetic quaternary ammonium compound derived from scopolamine, classified among belladonna alkaloids, semisynthetic quaternary ammonium compounds (ATC A03BB05).atcddd.fhi+4
It acts as a potent muscarinic receptor antagonist on the smooth muscles of the gastrointestinal tract, reducing acetylcholine‑mediated contractions and spasms and thereby alleviating abdominal pain.wikipedia+4
Because of its quaternary structure, cimetropium bromide has poor penetration across the blood–brain barrier and shows fewer central nervous system effects than tertiary anticholinergics such as atropine or scopolamine.drugbank+3

Indications and clinical use

Cimetropium bromide is indicated mainly for functional gastrointestinal disorders, particularly irritable bowel syndrome (IBS) with pain and constipation, and other painful conditions of the gastrointestinal, biliary and genitourinary tracts.pubmed.ncbi.nlm.nih+4
It has been used as a pre‑endoscopic medication and in some countries (e.g. Italy) under trade names such as Alginor for colicky abdominal pain and preparation for diagnostic procedures.drugs.ncats+2
Randomized studies in IBS show objective shortening of whole‑gut transit time in constipated patients and improvement of global clinical condition, whereas patients with already rapid transit do not benefit significantly.pubmed.ncbi.nlm.nih

Example clinical use

In adults with IBS‑C, oral cimetropium bromide given for several weeks reduced total gut transit time from roughly 80 to 60 hours and improved global symptom scores compared with placebo in one controlled trial.pubmed.ncbi.nlm.nih

Adverse effects, contraindications and toxicity

Cimetropium bromide shares the typical peripheral anticholinergic adverse‑effect profile: dry mouth, constipation, urinary difficulty or retention, tachycardia and palpitations, pupil dilation with blurred vision and photophobia, flushing and reduced bronchial secretions.1mg+2
It may cause drowsiness and sleepiness; therefore, patients are advised not to drive or operate machinery if affected.1mg
Contraindications include hypersensitivity to the drug, narrow‑angle glaucoma, significant prostatic enlargement, urinary retention, paralytic ileus, pyloric stenosis, reflux esophagitis and myasthenia gravis; caution is needed in patients with cardiovascular, respiratory, thyroid or neurological disorders, children with fever or diarrhoea, and those at risk of arrhythmias or hypertension.medpedia.framar+1

From a toxicology standpoint, overdose is expected to present with exaggerated anticholinergic effects—marked tachycardia, pronounced dry mouth and skin, urinary retention, ileus, visual disturbances and possibly confusion in susceptible individuals—though central manifestations are limited by poor CNS penetration.drugbank+3
Compared with tertiary belladonna alkaloids, cimetropium’s quaternary structure confers lower risk of central toxicity but does not reduce peripheral risks in vulnerable patients such as those with glaucoma or significant prostatic hypertrophy.atcddd.fhi+5

Use during pregnancy and lactation (lactology focus)

There are no robust, dedicated human studies on cimetropium bromide in breastfeeding mothers, and the molecule has not been widely marketed globally, which limits direct lactation data.pubchem.ncbi.nlm.nih+4
As a quaternary ammonium compound with poor oral bioavailability and limited systemic penetration, transfer into breast milk and oral absorption by the breastfed infant are expected to be low, although this remains inferred rather than proven.wikipedia+3

In infantile colic, evidence does not support routine use of cimetropium bromide; available reviews highlight lack of benefit and prefer probiotic approaches, underscoring the need to avoid exposing infants to anticholinergic agents unnecessarily.synapse.patsnap+2
Given the class‑related risks (anticholinergic effects on gut motility, urinary tract and eyes), most lactation‑safety frameworks would recommend: short‑term, lowest effective maternal dose; avoidance in preterm or medically fragile infants; and monitoring of the breastfed infant for decreased feeding, constipation, urinary retention, unusual sleepiness or poor weight gain.drugbank+3

During pregnancy, quaternary antimuscarinics are generally used cautiously, reserved for clear indications, because anticholinergic‑induced changes in maternal gut motility or heart rate can complicate existing obstetric conditions and data on teratogenicity are limited.drugbank+3

Practical toxicology–lactology guidance for clinicians

For breastfeeding women with IBS or functional abdominal pain, cimetropium bromide can be considered when first‑line non‑pharmacological strategies and better‑studied medications are ineffective, especially if a purely peripheral anticholinergic is preferred over centrally acting alternatives.drugs.ncats+4
Before prescribing, clinicians should review contraindications (glaucoma, prostatic enlargement, urinary retention, severe constipation, myasthenia gravis) and discuss potential anticholinergic adverse effects with the mother, including how to recognize symptoms in herself and the infant.medpedia.framar+1

If used during lactation, recommended safeguards include: limiting treatment duration, using the minimal effective dose, timing doses just after breastfeeding to reduce peak exposure, and reassessing necessity frequently.wikipedia+2
Documenting informed consent and providing clear written instructions about monitoring the child’s stool pattern, urine output, feeding behaviour and level of alertness is advisable in toxicology‑oriented practice.synapse.patsnap+2

Brief table: key properties